Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Should You Buy?

Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $198.51, but opened at $215.00. Genmab A/S shares last traded at $215.00, with a volume of 158 shares.

Genmab A/S Stock Performance

The stock has a market capitalization of $14.20 billion, a price-to-earnings ratio of 12.19 and a beta of 0.91. The firm's fifty day simple moving average is $208.14 and its 200 day simple moving average is $205.77.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $3.05 EPS for the quarter, topping the consensus estimate of $1.88 by $1.17. The firm had revenue of $765.14 million for the quarter, compared to the consensus estimate of $761.09 million. Genmab A/S had a net margin of 35.11% and a return on equity of 19.23%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.